August 2, 2022 — At what cost can we decide that obesity care is worth the money? Until now, the answer has largely been to refuse considering this question. But as the cost of untreated obesity adds up, it’s becoming impossible to dodge the question anymore and an increasing number of serious analyses are underway. The Institute for Clinical […]
July 14, 2022 — We’ve all got our reading assignments. The Institute for Clinical and Economic Review (ICER) has released its draft report on effectiveness and value for the current options in obesity medicine. There’s a lot to process in there. But the bottom line is clear enough. Phentermine/topiramate (Qsymia) offers the best value, says the report. The most […]
December 8, 2020 — What we have here is a bit of a love-hate story. In the midst of the COVID pandemic, Britain’s NHS has received an outpouring of love. But for folks living with obesity in the UK, it’s a little harder to find some of that love. Our own research suggests that some of the strongest weight […]
December 3, 2020 — We didn’t expect this: COVID-19 is a boon to the health insurance industry. Despite a health crisis killing someone every minute in the U.S., costs for medical care are down. That’s because of people avoiding or delaying healthcare – possibly putting their health at risk. But for health insurers, that means a big increase in […]
September 21, 2019 — Holy grail? Game-changer? These superlatives were flying around as FDA approved Rybelsus – oral semaglutide – yesterday for type 2 diabetes. We don’t know about all that puffery, but it’s clear enough that this approval is a big deal. Oral semaglutide will be the first ever GLP-1 agonist in a pill. Up until now, taking […]
